NCT03123978View on ClinicalTrials.gov

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 9, 2017

Primary Completion Date

January 14, 2022

Study Completion Date

April 19, 2022

Conditions
Metastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer
Interventions
DRUG

Enzalutamide

Given PO

DRUG

Niclosamide

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Pandomedx
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Pandomedx

OTHER

lead

Mamta Parikh

OTHER